Although much fervor has surrounded agents targeting PD-1 and PD-L1 in other malignancies due to impressive and durable responses, enthusiasm has waned for utilizing these agents in AML as a result of minimal improvement in responses and survival. The gene discussed is CD274; the disease is acute myeloid leukemia.